Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.
Actinium’s radiotherapy push gains IP depth as ATNM-400 heads to SNMMI 2026
Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.
Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?
Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.
How Full-Life Technologies is using US$150m to push beyond platform promise
Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.
Convergent Therapeutics heads to ASCO 2026 with Phase 2 CONV01-alpha data in Lu-PSMA pretreated prostate cancer
Convergent Therapeutics will present Phase 2 CONV01-alpha data at ASCO 2026. Find out what this could mean for post-Lu-PSMA prostate cancer care.
Why BIOEMTECH and NorthStar Medical Radioisotopes’ Actinium-225 agreement matters for preclinical alpha therapy development
BIOEMTECH secures Actinium-225 supply from NorthStar. Find out why isotope access now defines radiopharmaceutical development timelines.
Can Actinium’s ATNM-400 radiotherapy reshape treatment for resistant breast cancer?
Actinium Pharmaceuticals, Inc. has presented new preclinical data for its alpha-particle radiotherapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting potent anti-tumor activity across hormone receptor–positive, triple-negative, and therapy-resistant breast cancer models. The findings suggest that ATNM-400 could become a differentiated treatment option for patients with tumors that have progressed after […]